Why the study?
Does indobufen reduce thromboxane biosynthesis compared to aspirin in patients with unstable angina?
Population
20 patients (15 men and 5 women aged 59+/-10 years) with unstable angina
Comparison
Indobufen 200 mg oral twice daily (BID) short-term vs Aspirin 320 mg/d short-term
Design
RCT, randomized
Follow-up
short-term (6 to 18 consecutive urine samples)
Authors
Loading...
Indobufen may offer superior thromboxane suppression in unstable angina; extends RCT evidence for alternative antiplatelet strategies beyond aspirin.
Does indobufen reduce thromboxane biosynthesis compared to aspirin in patients with unstable angina?
Indobufen more effectively suppresses thromboxane biosynthesis than aspirin in unstable angina, likely due to its ability to inhibit extraplatelet PGHS-2.
Cipollone et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: